Assistant Attending Molecular Geneticist
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Dr. Debyani Chakravarty is a Molecular Geneticist and an Assistant Attending Member of the Molecular Diagnostics Service of the Department of Pathology and Laboratory Medicine (DPLM) at the Memorial Sloan Kettering Cancer Center (MSK). Dr. Chakravarty specializes in cancer genomics and the accurate clinical interpretation of patient-tumor molecular profiles. Working with medical oncologists and molecular pathologists she guides patient-centric care by providing information about the clinicobiologic significance of genomic alterations found in cancer. Dr. Chakravarty is the co-developer and scientific lead of MSK’s FDA-recognized precision oncology knowledge base, OncoKB. OncoKB provides evidence-based interpretations of the clinical actionability of patient-tumor genetic alterations and annotates ~15,000 molecular pathology sequencing reports at MSK per year. Under Dr. Chakravarty’s leadership, OncoKB became the first and only somatic cancer variant database to be partially recognized by the FDA. Dr. Chakravarty is a primary author of the OncoKB index paper and the first author of the American Society of Clinical Oncology (ASCO) provisional clinical opinion on Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer. From 2018 to 2022, she was the Co-Director for the Variant Interpretation for Cancer Consortium (VICC) a driver project for the Global Alliance for Genomics Health (GA4GH). Dr. Chakravarty is also a frequent advisory participant in projects for the European Society for Medical Oncology (ESMO) Precision Medicine Working Group. Prior to her current role, Dr. Chakravarty received her BA cum laude in Chemistry and Economics from Boston University in 2000, a Ph.D in Biochemistry and Molecular Biology from Georgetown University in 2007 and conducted two translational cancer biology research fellowships at MSK from 2007 to 2014. Dr. Chakravarty’s research characterizes the genomic landscape of pancreatic cancer in patients from diverse and underserved populations and identifies methods to increase access to precision oncology treatment strategies for these same patient communities.
Disclosure information not submitted.
OncoKB: MSK's FDA-Recognized Clinical Grade Precision Oncology Knowledge Bases
Thursday, November 16, 2023
1:15 PM - 1:45 PM MST